Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFT8919 in Advanced or Metastatic NSCLC With EGFR Mutations
NCT06641609Phase 1Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of CFT8919 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Objective Response Rate up to 104 weeks, Maximum Tolerated Dose at 1 year and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
CFT8919
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06641609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641609.